It came as a number of banks behind the IPO launched coverage of the company, with UBS suggesting a number of potential acquisition targets sit in wait.
New York-listed Gener8 says 1,882,223 shares have been taken by its underwriters at a discount to the $14 per share offer price.
Gener8, which raised $210m from its float, had granted underwriters the option take in up to 2,250,000 shares.
